Literature DB >> 26154092

Thyroid function, autoimmunity and nodules in hematological malignancies.

Patrizia Mondello1, Alessandro Sindoni2, Vincenzo Pitini1, Claudio Scisca1, Giuseppe Altavilla1, Salvatore Benvenga3.   

Abstract

OBJECTIVE: Hematological malignancies encompass a large spectrum of disease entities whose treatment by chemo/radiotherapy could lead to thyroid complications. To the best of our knowledge, no study has simultaneously addressed thyroid function, autoimmunity and nodularity. Therefore, we decided to conduct one.
MATERIALS AND METHODS: We evaluated 82 Caucasian patients (36 women and 46 men), who were treated at our Oncology division for hematological malignancies (multiple myeloma, chronic myeloid leukemia, chronic lymphatic leukemia, non-Hodgkin lymphoma and polycythemia vera) and compared them with a control group of 104 patients. Patients who had received or were receiving external head/neck radiotherapy were excluded. All oncological patients and control individuals underwent thyroid ultrasonography and thyroid function and autoimmunity tests.
RESULTS: A lower prevalence of enlarged thyroid and nodules were found in patients with respect to controls. The rate of thyroid nodules was the highest in multiple myeloma and polycythemia vera, and the lowest in chronic lymphatic leukemia. Non-Hodgkin lymphoma patients had the smallest thyroid nodules while men with multiple myeloma the biggest ones. No patient had hypothyroidism, while 5.6% of patients had subclinical hyperthyroidism. In contrast, within the control group the rates of hypothyroidism and hyperthyroidism, overt and subclinical, were 3.8%, 20.2%, 0% and 0% respectively. Moreover, the overall rate of thyroid autoantibody positiveness in patients was significantly lower than controls.
CONCLUSION: In our experience, we found a significantly lower prevalence of thyroid abnormalities in hematologic patients who underwent chemotherapy, but not radiotherapy, with respect to controls.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26154092     DOI: 10.1590/2359-3997000000044

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  3 in total

1.  Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?

Authors:  P Mondello; M Mian; V Pitini; S Cuzzocrea; A Sindoni; M Galletti; M Mandolfino; D Santoro; S Mondello; C Aloisi; G Altavilla; S Benvenga
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

2.  The various faces of hyperthyroidism.

Authors:  Christian A Koch; Roberto Vita; Salvatore Benvenga
Journal:  J Clin Transl Endocrinol       Date:  2020-06-05

3.  Thyroid carcinoma associated with other primary neoplasms, a single center study.

Authors:  Katalin Gabora; Ovidiu Bălăcescu; Adrian Trifa; Ana Maria Morariu; Bogdan Pop; Simona Vişan; Bogdan Fetica; Andra Piciu; Doina Piciu
Journal:  Med Pharm Rep       Date:  2022-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.